Advances in cancer immunotherapy 2019 - latest trends.

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. · 2019

Read Advances in cancer immunotherapy 2019 - latest trends. by Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6585101.txt.

Description

Kruger and co-authors round up the latest trends in cancer immunotherapy as of 2019, writing in the Journal of Experimental and Clinical Cancer Research. Two engines drive the field: checkpoint inhibitors that release T-cell brakes, and CAR T cells engineered to hunt cancer. The review distills the newest clinical and translational findings from major meetings and journals.

For checkpoint blockade, the frontier is combinations — with chemotherapy, radiation and each other — plus use around surgery, new tumor types, response prediction and safer toxicity handling. For CAR T cells, larger cohorts confirmed the early results in leukemia and lymphoma, while strategies multiply to carry the approach into other blood cancers and solid tumors. A geographic note closes the survey: CAR T trials now cluster in the US and China.

Catalog record

CREATORKruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6585101

Browse the full library · About the Tower of Babel